Get the Stockscreener App
104.80
1.05%
-1.11
Nuvalent Inc stock is traded at $104.80, with a volume of 524.24K.
It is down -1.05% in the last 24 hours and up +8.01% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$105.91
Open:
$106.37
24h Volume:
524.24K
Relative Volume:
0.90
Market Cap:
$8.14B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-26.87
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
-4.38%
1M Performance:
+8.01%
6M Performance:
+34.51%
1Y Performance:
+20.71%
1-Day Range:
$103.52
$107.49
1-Week Range:
$103.52
$111.94
52-Week Range:
$55.53
$112.88
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
104.80 | 8.22B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-12-25 | Initiated | Canaccord Genuity | Buy |
| Oct-16-25 | Resumed | Stifel | Buy |
| Oct-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Nuvalent announces public offering of common stock - MSN
Nuvalent, Inc. $NUVL Shares Acquired by Braidwell LP - MarketBeat
Is Nuvalent Inc stock a defensive play in 2025Trade Analysis Summary & Expert Curated Trade Setup Alerts - moha.gov.vn
Natixis Makes New $1.75 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat
Insider Selling: Nuvalent (NASDAQ:NUVL) CFO Sells 7,084 Shares of Stock - MarketBeat
HighVista Strategies LLC Has $3.85 Million Stake in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent appoints Ron Squarer to board of directors By Investing.com - Investing.com Nigeria
Trading the Move, Not the Narrative: (NUVL) Edition - news.stocktradersdaily.com
Insider Sell Alert: Alexandra Balcom Sells Shares of Nuvalent Inc (NUVL) - GuruFocus
Nuvalent appoints Ron Squarer to board of directors - Investing.com
Nuvalent Insider Sold Shares Worth $781,537, According to a Recent SEC Filing - marketscreener.com
Ron Squarer Joins Nuvalent Board as Independent Director - TipRanks
Nuvalent Appoints Ron Squarer to Board of Directors - Finviz
Nuvalent, Inc. Announces Board Changes - marketscreener.com
Nuvalent (Nasdaq: NUVL) taps Ron Squarer for board as zidesamtinib launch prep builds - Stock Titan
Nuvalent, Inc. (NUVL) is a buy on lung cancer treatment prospects - MSN
Nuvalent (NUVL) Valuation After FDA Breakthrough Designation and Investor Optimism in Lung Cancer Franchise - Sahm
Nuvalent, Inc. $NUVL Shares Acquired by Walleye Capital LLC - MarketBeat
Stempoint Capital LP Has $4.57 Million Stake in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent’s Clinical and Financial Momentum Captivates Investors - AD HOC NEWS
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects - Insider Monkey
Norges Bank Buys Shares of 374,597 Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Nuvalent (NUVL) Price Target Increased by 11.46% to 142.80 - Nasdaq
Affinity Asset Advisors LLC Reduces Position in Nuvalent, Inc. $NUVL - MarketBeat
Russell Investments Group Ltd. Sells 28,747 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Rhumbline Advisers Has $5.04 Million Stock Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Layoff Watch: Is Nuvalent Inc stock trading at a premium valuationEarnings Growth Summary & Free Expert Verified Stock Movement Alerts - BỘ NỘI VỤ
NUVL: Late-stage oncology assets show strong efficacy and safety, with first approvals targeted for 2026 - TradingView
Will Nuvalent Inc. stock attract more institutional investorsMarket Sentiment Summary & Long-Term Safe Investment Ideas - Newser
Nuvalent Insider Sold Shares Worth $434,319, According to a Recent SEC Filing - marketscreener.com
Nuvalent Chief Development Officer Sells Shares - TradingView
Officer Noci Sells 4,000 ($434.3K) Of Nuvalent Inc [NUVL] - TradingView
Nuvalent (NUVL) Stock Analysis Report | Financials & Insights - Benzinga
American Century Companies Inc. Boosts Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Creative Planning Buys 9,079 Shares of Nuvalent, Inc. $NUVL - MarketBeat
(NUVL) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Returns Recap: Is Nuvalent Inc. stock trading near support levelsJuly 2025 Volume & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference - Eastern Progress
Nuvalent (NASDAQ:NUVL) Director Sells $639,814.50 in Stock - MarketBeat
Does Nuvalent’s Recent Trial Success Justify the Stock’s 36% 2025 Rally? - Yahoo Finance
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Nuvalent Director and 10% Owner Matthew Shair Sells 7,500 Shares - TradingView
Nuvalent to Participate in the Piper Sandler 37th Annual Healthc - GuruFocus
Nuvalent: Deerfield funds sell $70.8m in NUVL stock By Investing.com - Investing.com South Africa
Nuvalent (NUVL) Receives a New Rating from Truist Financial - The Globe and Mail
Nuvalent closes $500 million public offering of common stock By Investing.com - Investing.com India
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders - Finviz
Nuvalent: Deerfield funds sell $70.8m in NUVL stock - Investing.com
Nuvalent Announces Closing of Public Offering of Common Stock an - GuruFocus
Nuvalent Closes Public Offering of Common Shares - marketscreener.com
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):